- OPKO Health (OPK) and Entera Bio (ENTX, Financial) are set to present their abstract for OPK-88006, a first-in-class dual GLP-1/glucagon tablet, at the ENDO 2025 annual meeting in San Francisco.
- The OPK-88006 candidate is to be developed in both a once-daily oral tablet and a weekly injectable form aimed at treating obesity and metabolic disorders.
- The companies plan to file an Investigational New Drug (IND) application with the FDA by the end of 2025.
OPKO Health, Inc. (OPK) and Entera Bio Ltd. (ENTX) have announced that their collaborative abstract on the first-in-class oral dual GLP-1/glucagon agonist, OPK-88006, has been selected for presentation at the ENDO 2025 annual meeting scheduled in San Francisco. This innovative drug candidate is being developed concurrently as a once-daily tablet and a weekly subcutaneous injection, targeting obesity and metabolic disorders. The oral format uses OPKO's long-acting oxyntomodulin analog combined with Entera's proprietary N-Tabâ„¢ technology.
The companies aim to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) later in 2025. This filing will facilitate the commencement of Phase 1 clinical trials for both the oral and injectable forms. The presentation at ENDO 2025 underscores the promising potential of OPK-88006, affirming the scientific community's recognition and validating preclinical findings.
Miranda Toledano, Chief Executive Officer of Entera, highlighted the rarity and significance of oral peptides in metabolic therapy, positioning this development as a critical milestone. The dual-format strategy not only meets a gap in the current treatment landscape but could also enhance patient compliance and clinical outcomes, leveraging the complementary mechanisms of GLP-1 and glucagon for effective weight management.
